Why is "ALK inhibitor" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-02 15:04:35
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it.
A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion, although as of 2020, over 92 fusion partners have been discovered in ALK+ NSCLC. For each fusion partner, there can be several fusion variants depending on the position the two genes were fused at, and this may have implications on the response of the tumour and prognosis of the patient.
Related Topics
Trending Topic Today
Search Interest Perspective
-
Case report: ALK inhibitor-induced transformation of ALK fusion-positive lung adenocarcinoma to large cell neuroendocrine carcinoma - Nature
-
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK–driven lung cancer by concurrent integrin and MET signaling - Science | AAAS
-
ALK and Lung Cancer - American Lung Association
-
Nuvalent presses ahead in ALK | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms race - ScienceDirect.com
-
Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC - CancerNetwork
-
FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC - Oncology Nursing News
-
First Approval for New ALK Inhibitor - American Association for Cancer Research (AACR)
-
From Early Stage to Resistance: ALINA Study Insights and ALK Inhibitor Sequencing Strategies - OncLive
-
Brigatinib vs Crizotinib in ALK Inhibitor–Naive Patients With ALK-Positive Advanced NSCLC - The ASCO Post
-
NVL-655 overcomes ALK inhibitor limitations - BioWorld News
-
Lorbrena Effective as Initial Treatment of ALK-Positive NSCLC - National Cancer Institute (.gov)
-
ALK inhibitor may overcome treatment resistance in pediatric neuroblastoma - Oncology Central
-
Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial - CancerNetwork
-
DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor–resistant lung cancer therapy - Nature
-
ALK Inhibitor Sequencing in NSCLC - OncLive
-
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients - Nature
-
Can a Third-Generation ALK Inhibitor Improve Outcomes in NSCLC? - CancerNetwork
-
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features - Nature
-
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status - Nature
-
QiLu’s ALK inhibitor meets Phase III primary endpoint in NSCLC - Clinical Trials Arena
-
China’s NMPA approves Pfizer’s third-generation ALK inhibitor Lorbrena in NSCLC - BioWorld News
-
Xcovery edges closer to FDA approval for NSCLC ALK inhibitor - Pharmaceutical Technology
-
Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT - Oncodaily
-
ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types - MedPage Today
-
Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer - Fierce Pharma
-
-driven neuroblastoma is associated with AXL activation and induction of EMT - Nature
-
FDA Approves Fourth ALK Inhibitor for Lung Cancer - American Association for Cancer Research (AACR)
-
FDA Grants Priority Review for Alecensa in Some ALK-Positive NSCLC - Cure Today
-
Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis - Nature
-
Takeda’s dream of a first-line ALK inhibitor supported by late-stage data - BioPharma Dive
-
Case report: A patient with ALK-positive large B-cell lymphoma benefited from myeloma-like treatment combined with the ALK inhibitor lorlatinib - Frontiers
-
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results - Nature
-
Roche snags postsurgery FDA nod for Alecensa, eyes even broader lung cancer use - Fierce Pharma
-
Small Study Suggests ALK Targeting May Be of Benefit in Adult Neuroblastoma - The ASCO Post
-
NVL-655 Shows Strong Efficacy in Heavily Pretreated ALK+ NSCLC - OncLive
-
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer - NEJM
-
Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment - Nature
-
Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement - Haematologica
-
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer - NEJM
-
Triple data take Nuvalent's market cap above $3bn | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms - Frontiers
-
New research suggests potential combination therapy option for children with neuroblastoma to prevent resistance to treatment - Neuroblastoma UK
-
Dr. Xia on the Frontline Treatment Landscape of ALK-Positive NSCLC - OncLive
-
ALK Inhibitors Market: A Comprehensive Overview of Current Trends and Future Projections | DelveInsight - PR Newswire
-
Adjuvant alectinib is a new treatment strategy for resected ALK-positive NSCLC - ESMO Daily Reporter
-
F isotopologues of the ROS1/ALK inhibitor lorlatinib - Nature
-
Ensartinib Receives FDA Approval for ALK-Positive Locally Advanced or Metastatic NSCLC - AJMC
-
Lorlatinib in Second- or Third-Line Treatment of ALK-Positive Metastatic Non–Small Cell Lung Cancer - The ASCO Post
-
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - MedPage Today
-
Targeted Therapies Extend Overall Survival in Patients with Stage 4 ALK-Positive Lung Cancer - Cure Today
-
ALK fusions in the pan-cancer setting: another tumor-agnostic target? - Nature
-
FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer - National Cancer Institute (.gov)
-
Pfizer shares positive five-year results for Lorbrena in advanced lung cancer - PMLiVE
-
New First-Line Option for Advanced ALK-Positive Lung Cancer - MedPage Today
-
Pfizer’s new lung cancer drug bags US clearance - PharmaTimes
-
Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer - Cancer Health
-
ALK inhibitors as good as chemotherapy for NSCLC patients - MDLinx
-
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer - NEJM
-
ALK variants, PD-L1 expression, and their association with outcomes in ALK -positive NSCLC patients - Nature
-
Crizotinib Chronicles - C&EN
-
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F - NEJM
-
Pfizer gets sales nod for ALK-positive lung cancer drug - koreabiomed.com
-
Prof Ben Solomon: ALK inhibitor effective in first line therapy for NSCLC - the limbic
-
Crizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor - NEJM
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.